ADVANCED DATA ENTRY

Story began in 1979 when Dr Rolland-Yves Mauvernay, convinced that many useful therapeutic products were abandoned before reaching their full potential, decided to found the Swiss-based Debiopharm Group. Having started with only two people, Debiopharm is now a group of five companies active in the life science areas of drug development, GMP manufacturing of proprietary drugs, diagnostic tools and investment management. Together with his son Thierry Mauvernay, they have built a team of well over 420 dedicated professionals. The Group is now headed up by Mr Thierry Mauvernay, driven by the same passion as his father. He is fully committed to the group’s current activities and planning the future to ensure long-term continuity. BUSINESS What we do We are a pharmaceutical research, development and production facility, inspected and registered with the main regulatory authorities. BUSINESS MODEL The Company is a world leader in polylactic-co-glycolic acid (PLGA)-based injectable, sustained-release technology. It has been used for one of our best-selling product Decapeptyl®, a novel injectable controlled-release formulation of triptorelin – a gonadotropin releasing hormone (GnRH) agonist analogue. This mode of administration developed by Debiopharm Research & Manufacturing relies on the active substance being “encapsulated” in a PLGA polymer to allow gradual dissolution and distribution of the substance in the patient’s body.